Halozyme prices $1.3B convertible senior notes due 2033 at 1.50%; upsized from $1.05B

HALOZYME THERAPEUTICS, INC.

$1.3B aggregate principal of 1.50% convertible notes due Oct 1, 2033, upsized from $1.05B; 13-day greenshoe for up to $200M.
Initial conversion price ~$139.84/share (27.5% premium above $109.68 close); cap price of capped calls ~$208.39/share.
Net proceeds ~$1.275B; ~$162.5M funds capped calls, remainder for note repurchases, working capital, acquisitions.
To repurchase ~$151.7M of 0.25% 2027 notes (cost ~$217.0M) and $220.0M of 1.00% 2028 notes (cost ~$435.5M).
Closing expected Sept 22, 2026; offering private to QIBs under Rule 144A; settle conversions in cash plus shares if applicable.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.